Naplesbird, adding more would be a good idea, but
Post# of 85484
This Catalent/Paragon deal is HUGE. You can see the connection to Merck in their management, and look at the number of facilities Catalent will now control (locations in several states). This new plant will specialize in nebulizers, vaporizers, and sprays but will produce a wide range of additional products. When proposed, the new facility was only intended to be about 150,000 square feet --- now it will be 200,000 square feet. Apparently they have anticipated the need for additional capacity. Imagine the expected revenue. A 1.2 billion dollar investment in new production capacity really speaks for itself.
The new facility is set up to be GMP complient both in the United States and in Europe. The facility is also early stage FDA approved so no one needs to guess where this is going.
Kgem